Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,034 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,034 shares of the stock in a transaction dated Friday, August 28th. The stock was acquired at an average cost of $48.35 per share, with a total value of $49,993.90. Following the transaction, the chief operating officer directly owned 2,070 shares in the company, valued at approximately $100,084.50. This trade represents a 99.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Stock Down 2.0%

Shares of NASDAQ:PLSE opened at $47.57 on Friday. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $50.90. The firm has a 50 day moving average of $35.38 and a 200 day moving average of $27.00.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. On average, sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PLSE. Russell Investments Group Ltd. lifted its holdings in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares during the period. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences in the 2nd quarter worth approximately $28,000. Alliancebernstein L.P. raised its position in Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after buying an additional 1,300 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PLSE. Mizuho set a $45.00 target price on Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group increased their price target on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.